Nanox AI Ltd. Enters into Distribution Agreement with Technologic s.r.l., an Affiliate of Tecnologie Avanzate, to Commercialize Nanox.AI Bone Solution in Italy
The collaboration is expected to draw on Tecnologie Avanzate's medical technology experience and Italian market knowledge.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nano-X Imaging (NASDAQ: NNOX) announced its subsidiary Nanox AI signed a distribution agreement with Technologic to commercialize HealthOST in Italy.
Technologic is affiliated with Tecnologie Avanzate but is the contractual counterparty. Nanox expects the collaboration to support its Italian commercial expansion by drawing on Tecnologie Avanzate's medical technology experience and local market knowledge. HealthOST, Nanox.AI's Bone solution, is designed to analyze the spine using eligible routine CT scans and support assessment of musculoskeletal disease, including osteoporosis.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointSigned distribution agreement with Technologic supports commercialization of Nanox.AI's HealthOST bone solution in Italy.
Negative
- None.
Previous AI Reports
-
Vertec received exclusive UK HealthOST resale rights, subject to minimum annual license commitments.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
CT scans medical
osteoporosis medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Agreement aims to expand the commercial reach of Nanox.AI's Bone Solution in the Italian healthcare market.
Collaboration leverages Tecnologie Avanzate's 50 years of experience in the Italian medical technology market, established healthcare industry relationships, and expertise in introducing advanced medical technologies.
PETACH TIKVA, Israel, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Nano-X Imaging Ltd. (NASDAQ: NNOX) ("Nanox" or the "Company"), a leader in innovative medical imaging technology, today announced that its subsidiary, Nanox AI Ltd. ("Nanox AI"), has entered into a distribution agreement with Technologic s.r.l. ("Technologic"), an Italian company affiliated with Tecnologie Avanzate, for the commercialization of Nanox.AI’s Bone solution, HealthOST, in Italy.
The agreement is intended to support the expansion of Nanox.AI’s commercial presence in Italy. The collaboration is expected to draw on the medical technology experience and local market knowledge associated with Tecnologie Avanzate, which reports a history dating to 1974. The contractual counterparty is Technologic s.r.l.
Nanox.AI’s HealthOST is designed to help clinicians unlock valuable insights from eligible routine CT scans, providing qualitative and quantitative analysis of the spine to support the evaluation and assessment of musculoskeletal disease such as osteoporosis.
By leveraging imaging studies already performed for other clinical purposes, Nanox.AI aims to help healthcare providers recognize patients who may benefit from further evaluation and timely intervention, supporting a more proactive approach to bone health management.
Erez Meltzer, Chief Executive Officer and Acting Chairman of Nanox, said: “This agreement expands the reach of HealthOST, our AI-powered bone solution, into the Italian market and marks another step in our efforts to bring advanced bone health assessment capabilities to healthcare providers worldwide.”
“With more than 50 years of experience in bringing innovative medical technologies to the Italian healthcare market, we recognize the growing potential of artificial intelligence to enhance clinical workflows and support better patient care,” said Vittorio Catolla Cavalcanti, CEO of Technologic s.r.l. “Our collaboration with Nanox.AI reflects our commitment to providing healthcare professionals with advanced solutions that deliver meaningful clinical value. We look forward to introducing HealthOST to healthcare providers across Italy and supporting its adoption in clinical practice.”
About Nanox
Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform.
Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.
Nanox’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.
The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.
By integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide. For more information, please visit www.nanox.vision
About Nanox.AI
Nanox.AI is the deep-learning medical imaging analytics subsidiary of Nanox. Nanox.AI solutions are developed to target highly prevalent chronic and acute diseases affecting large populations around the world. Leveraging AI, Nanox.AI helps clinicians extract valuable and actionable clinical insights from medical imaging that otherwise may go unnoticed, potentially initiating further medical assessment to establish individual preventative care pathways for patients. For more information, please visit www.nanox.vision/ai.
Forward-Looking Statements
This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of Nanox’s liquidity to pursue its complete business objectives, and substantial doubt regarding its ability to continue as a going concern; (iv) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (v) Nanox’s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (vi) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vii) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (viii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (ix) Nanox’s ability to conduct business globally; (x) changes in global, political, economic, business, competitive, market and regulatory forces; (xi) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xii) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xiii) potential litigation associated with our transactions.
For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.
Contacts
Media Contact:
Ben Shannon
ICR Healthcare
NanoxPR@icrinc.com
Investor Contact:
Mike Cavanaugh
ICR Healthcare
mike.cavanaugh@icrhealthcare.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who is Nanox AI's distribution partner for HealthOST in Italy?
Technologic is Nanox AI's contractual distribution partner for commercializing HealthOST in Italy. Technologic is affiliated with Tecnologie Avanzate; Tecnologie Avanzate itself is not the contractual counterparty.